The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review

被引:1120
作者
Younossi, Zobair M. [1 ,2 ,3 ]
Golabi, Pegah [1 ,2 ,3 ]
Paik, James M. [1 ,2 ,3 ]
Henry, Austin [1 ]
Van Dongen, Catherine [1 ]
Henry, Linda [1 ,2 ,3 ]
机构
[1] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
[2] Inova Fairfax Med Campus, Ctr Liver Dis, Dept Med, Falls Church, VA USA
[3] Inova Hlth Syst, Inova Med, Falls Church, VA USA
关键词
PREVALENCE; METAANALYSIS; REGRESSION; BURDEN; UPDATE; BIAS;
D O I
10.1097/HEP.0000000000000004
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. Approach and Results: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using randomeffects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N = 9,361,716) met eligibility criteria. Across the study period (1990-2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%-32.32%) and 30.69% (28.4-33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59-29.33) in 1990-2006 to 38.00% (33.71-42.49) in 2016-2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46-31.87) in 1990-2006 to 34.59% (29.05-40.57) (p = 0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%-59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%-45.22%), South Asia (33.83%, 22.91%-46.79%), South-East Asia (33.07%, 18.99%-51.03%), North America (31.20%, 25.86%-37.08%), East Asia (29.71%, 25.96%-33.76%), Asia Pacific 28.02% (24.69%-31.60%), Western Europe 25.10% (20.55%-30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68-23.67) for all-cause mortality; 4.20 (1.34-7.05) for cardiac-specific mortality; 2.83 (0.78-4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00-2.21) for liver-specific mortality. Conclusions: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels.
引用
收藏
页码:1335 / 1347
页数:13
相关论文
共 41 条
  • [1] [Anonymous], 2022, Global Burden of Disease Study 2019 Results
  • [2] [Anonymous], 2012, World Health Day
  • [3] [Anonymous], Global Burden of Disease (GBD)
  • [4] A RANDOM-EFFECTS REGRESSION-MODEL FOR METAANALYSIS
    BERKEY, CS
    HOAGLIN, DC
    MOSTELLER, F
    COLDITZ, GA
    [J]. STATISTICS IN MEDICINE, 1995, 14 (04) : 395 - 411
  • [6] Role of Obesity and Lipotoxicity in the Development of Nonalcoholic Steatohepatitis: Pathophysiology and Clinical Implications
    Cusi, Kenneth
    [J]. GASTROENTEROLOGY, 2012, 142 (04) : 711 - U109
  • [7] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188
  • [8] Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States
    Doycheva, Iliana
    Issa, Danny
    Watt, Kymberly D.
    Lopez, Rocio
    Rifai, Ghassoub
    Alkhouri, Naim
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2018, 52 (04) : 339 - 346
  • [9] easl, Accessible lay summary on fighting fatty liver disease
  • [10] Bias in meta-analysis detected by a simple, graphical test
    Egger, M
    Smith, GD
    Schneider, M
    Minder, C
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7109): : 629 - 634